Skip to main content

Select Drug Profiles

Healthcare Innovation Viability: On the Edge of a Knife

Robert E. Henry

Why Financial Incentives Aren't Enough to Move the Needle on Compliance

Practice Management

Prescription Copay Reduction Program for Diabetic Employees: Impact on Medication Compliance and Healthcare Costs and Utilization

Kavita V. Nair, PhD, Kerri Miller, PharmD, BCPS, Joseph Saseen, PharmD, FCCP, BCPS, Pamela Wolfe, MS, Richard Read Allen, MS, Jinhee Park, CPhil, Ma, MS

Stakeholder Perspective

Improved Clinical Outcomes the True Value of Copay Reductions for Diabetic Employees, Despite Increased Overall Costs

by Geoffrey P. Cole, MD, MBA

Original Research

Partial Compliance with Antipsychotics Increases Mental Health Hospitalizations in Schizophrenic Patients: Analysis of a National Managed Care Database

Chris M. Kozma, PhD, Peter J. Weiden, MD

Stakeholder Perspective

Encouraging Compliance Key for Positive Outcomes in Schizophrenia/Chronic Diseases

by Paul Anthony Polansky, BSPharm, MBA

Original Research

Alzheimer's Disease: A Healthcare Burden of Epidemic Proportion

T. S. Dharmarajan, MD, FACP, AGSF, Srinivas G. Gunturu, MD

Stakeholder Perspective

The Challenge of Value-Based Benefit Design in Alzheimer's Disease

by Jeff Januska, PharmD

Practice Management

Recent Slowdown in National Health Expenditures Attributed to Growing Use of Generics

Dalia Buffery, MA, ABD

Conference Highlights AHA

Cost-Sharing Strategies Decrease Adherence to Statin Therapy

e-Prescribing: A Move Toward Appropriate Medication Use

Jack E. Fincham, PhD, RPh

Practice Management

Focus on Lowest Net Cost Drug Reduces Costs for Patients, Plan Sponsors

Dana H. Felthouse, MBA

Practice Management

Erythropoiesis-Stimulating Agents in a Meta-Stable State: Guidelines, Economics, and Policy in Flux

Stakeholder Perspective

The Clinical and Economic Complexity of Biologics

by F. Randy Vogenberg, PhD, FASHP

Page 236 of 244
Results 2351 - 2360 of 2438